


Figure 1



= SOLID SUPPORT

R = TERMINAL PROTECTING GROUP

FOR EXAMPLE:

DIMETHOXYSYTRITYL (DMT)

(1)
~~~~~


= CLEAVABLE LINKER

(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR  
INVERTED DEOXYABASIC SUCCINATE)


(2)  
~~~~~

= CLEAVABLE LINKER

(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
INVERTED DEOXYABASIC SUCCINATE)



INVERTED DEOXYABASIC SUCCINATE
LINKAGE



GLYCERYL SUCCINATE LINKAGE

Figure 2




Figure 3





Figure 4




POSITIONS (NN) CAN COMprise ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES
(eg. THYMIDINE) OR UNIVERSAL BASES

B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP THAT IS OPTIONALLY PRESENT

L = GLYCERYL or B THAT IS OPTIONALLY PRESENT

S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE that is optionally absent

Figure 5



lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro

italic lower case = 2'-deoxy-2'-fluoro

underline = 2'-O-methyl


ITALIC UPPER CASE = DEOXY

iB = INVERTED DEOXYABASIC

L = GLYCERYL MOIETY or iB OPTIONAL PRESENT

S = PHOSPHOROTHIOATE OR
PHOSPHORODITHIOATE OPTIONAL PRESENT


Figure 6



Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA)
Inventor: McSwiggan et al.
Atomey Docket No. 02-742-O (400.144)


Title RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA)

Figure 7



Title: RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA)
 Inventor: McSwiggen et al.
 Atomey Docket No. 02-742-O (400.144)
 Sheet 7 of 15

Figure 8



Title: RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA)
 Inventor: Michael J. Swigle et al.
 Attnomey Docket No. 02-742-O (400.144)
 Status: 8-651

Figure 9: Target site Selection using siRNA





Figure 10



$\text{R} = \text{O}, \text{S}, \text{N}$, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl
 $\text{B} = \text{Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).}$

Figure 11: Modification Strategy




Figure 12: Phosphorylated siNA constructs




Figure 13: 5'-phosphate modifications




Figure 14A: Inhibition of VEGF RNA expression using Stab 0/0 and Stab 9/10 siNA targeting VEGF RNA sequences




Figure 14B: Inhibition of VEGF RNA expression using Stab 7/8 siNA targeting VEGF RNA sequences

